Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813917 · ClinicalTrials.gov registry record · NA
Varenicline for the Treatment of Smokeless Tobacco
A NA study of Nicotine Dependence, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00813917 is a NA study of Nicotine Dependence that has completed, run by Mayo Clinic. The registered enrollment target is 76 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00813917, a NA study of Nicotine Dependence, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel mechanism of action of varenicline potentially circumvents the limitations of using nicotine replacement therapy or bupropion pharmacotherapy in ST users. The overall goal of this line of research is to develop effective pharmacologic treatments for ST users to increase long-term (≥ 6 months) abstinence rates. The central hypothesis of this application is that varenicline is efficacious for the treatment of ST users.
Conditions Studied
Interventions
- DRUG placebo
- DRUG varenicline
Study Locations (1)
Minnesota
- Nicotine Research Program - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00813917
The ClinicalTrials.gov registry entry for NCT00813917 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (59% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00813917 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00813917 about?
NCT00813917 is a clinical study titled "Varenicline for the Treatment of Smokeless Tobacco". Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel mechanism of action of vare...
What is the current status of trial NCT00813917?
This trial is currently completed. It is a NA study. The enrollment target is 76 participants. The study started on 2009-02. Estimated completion is 2011-01.
What conditions does trial NCT00813917 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT00813917?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG).
Who is sponsoring clinical trial NCT00813917?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00813917 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
RECRUITING · NA
-
NeuroControl of Nicotine Dependence
RECRUITING · NA
-
Abuse Liability and Appeal of Oral Nicotine Products
RECRUITING · NA
-
Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction
RECRUITING · NA
-
Young Adult Tobacco/Nicotine and Cannabis Co-use
RECRUITING · NA
-
Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.